Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib
- Details
- Category: Pfizer
Pfizer announced the initiation of a large, global Phase III clinical trial to evaluate the efficacy and safety of sunitinib malate, in combination with erlotinib, in previously treated patients with advanced non-small cell lung cancer (NSCLC). In addition, preliminary results from a Phase II study, presented at the International Association for the Study of Lung Cancer (IASLC) World Conference in Seoul, Korea, provided information on the safety and tolerability of sunitinib in combination with erlotinib in patients with advanced NSCLC.
ERBITUX® Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
- Details
- Category: Bristol-Myers Squibb
ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced that a Phase III study of ERBITUX® (Cetuximab) in combination with platinum-based chemotherapy (vinorelbine plus cisplatin) met its primary endpoint of increasing overall survival compared with chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC).
PLIVA Enters Oncology Business in Germany
- Details
- Category: Financial
PLIVA d.d. announced that its German subsidiary AWD.pharma GmbH & Co. KG. ("AWD") has signed an agreement to acquire O.R.C.A.pharm GmbH ("ORCApharm"), a privately owned specialty pharmaceutical company focused on the oncology market in Germany. Upon closing of the transaction, AWD will pay a fixed purchase price of EUR 21m and up to an additional EUR 13m based on the achievement of profitability milestones for 2007 and 2008.
Novo Nordisk is Rated Supersector Leader in the 2007 Dow Jones Sustainability Indexes
- Details
- Category: Novo Nordisk
Novo Nordisk ranks as best-in-class in healthcare - one of 18 global supersectors - in Dow Jones Sustainability Indexes, the world's leading indexes for sustainability-driven investment portfolios. This ranking, effective at the opening of equity markets on 24 September 2007, is a result of the latest global analysis of corporate sustainability leadership, based on a thorough analysis of companies' economic, environmental and social performance.
Dow Jones Sustainability Index Again Recognizes Abbott
- Details
- Category: Abbott
Abbott - the global health care company - was named to the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the third consecutive year. This selection recognizes Abbott's continued leadership in business, environmental and social performance.
Avastin approved in Europe for first-line treatment of patients with advanced lung cancer
- Details
- Category: Roche
Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.
CeNeS and ERGOMED Report Start of Recruitment for Phase II trial of CNS 5161 in cancer pain
- Details
- Category: Clinical Trials
CeNeS Pharmaceuticals plc (AIM: CEN) and the ERGOMED Group today announced that they have initiated recruitment into a Phase II study of the potential new pain drug CNS 5161. CNS 5161 is being developed under a co-development deal signed in July 2006 between CeNeS and ERGOMED.
More Pharma News ...
- AstraZeneca and Pozen To Start Phase III Trials With PN400
- Bayer intends to delist from the New York Stock Exchange
- Novartis to defend its intellectual property rights for Famvir®
- Boehringer Ingelheim announce major global strategic alliance in novel nanobody® therapeutics
- Novartis completes divestment program with transfer of Gerber baby foods business
- GlaxoSmithKline receives approval for Atriance® (nelarabine) in Europe
- RotaTeq® Proves to Maintain High Clinical Efficacy Two Years Post-Vaccination in Europe